Aescin Inhibits Herpes simplex Virus Type 1 Induced Membrane Fusion

Abstract

Infections with Herpes simplex virus can cause severe ocular diseases and encephalitis. The present study aimed to investigate potential inhibitors of fusion between HSV-1 and the cellular membrane of the host cell. Fusion and entry of HSV-1 into the host cell is mimicked by a virus-free eukaryotic cell culture system by co-expression of the HSV-1 glycoproteins gD, gH, gL, and gB in presence of a gD receptor, resulting in excessive membrane fusion and polykaryocyte formation. A microscopic read-out was used for the screening of potential inhibitors, whereas luminometric quantification of cell-cell fusion was used in a reporter fusion assay. HSV-1 gB was tagged at its C-terminus with mCherry to express mCherry-gB in both assay systems for the visualization of the polykaryocyte formation. Reporter protein expression of SEAP was regulated by a Tet-On 3 G system. The saponin mixture aescin was identified as the specific inhibitor (IC₅₀ 7.4 µM, CC₅₀ 24.3 µM, SI 3.3) of membrane fusion. A plaque reduction assay on Vero cells reduced HSV-1 entry into cells and HSV-1 cell-to-cell spread significantly; 15 µM aescin decreased relative plaque counts to 41%, and 10 µM aescin resulted in a residual plaque size of 11% (HSV-1 17 syn⁺) and 2% (HSV-1 ANG path). Release of the HSV-1 progeny virus was reduced by one log step in the presence of 15 µM aescin. Virus particle integrity was mainly unaffected. Analytical investigation of aescin by UHPLC-MS revealed aescin IA and -IB and isoaescin IA and -IB as the main compounds with different functional activities. Aescin IA had the lowest IC₅₀, the highest CC₅₀, and an SI of > 4.6.

Keywords

Aescin - Aesculus hippocastanum - Sapindaceae - Herpes simplex virus - HSV-1 - membrane fusion - plaque reduction - triterpene saponins

Publikationsverlauf

Eingereicht: 26. Juli 2024

Angenommen nach Revision: 01. Oktober 2024

Artikel online veröffentlicht:
23. Oktober 2024

• References

• 1 Smith G. Herpesvirus transport to the nervous system and back again. Annu Rev Microbiol 2012; 66: 153-176
• 2 Atanasiu D, Saw WT, Eisenberg RJ, Cohen GH. Regulation of herpes simplex virus glycoprotein-induced cascade of events governing cell-cell fusion. J Virol 2016; 90: 10535-10544
• 3 Gescher K, Hensel A, Hafezi W, Derksen A, Kühn J. Oligomeric proanthocyanidins from Rumex acetosa L. inhibit the attachment of herpes simplex virus type-1. Antiviral Res 2011; 89: 9-18
• 4 Gescher K, Kühn J, Lorentzen E, Hafezi W, Derksen A, Deters A, Hensel A. Proanthocyanidin-enriched extract from Myrothamnus flabellifolia Welw. exerts antiviral activity against herpes simplex virus type 1 by inhibition of viral adsorption and penetration. J Ethnopharmacol 2011; 134: 468-474
• 5 Rogalin HB, Heldwein EE. Characterization of vesicular stomatitis virus pseudotypes bearing essential entry glycoproteins gB, gD, gH, and gL of herpes simplex virus 1. J Virol 2016; 90: 10321-10328
• 6 Colpitts CC, Ustinov AV, Epand RF, Epand RM, Korshun VA, Schang LM. 5-(Perylen-3-yl)ethynyl-arabino-uridine (aUY11), an arabino-based rigid amphipathic fusion inhibitor, targets virion envelope lipids to inhibit fusion of influenza virus, hepatitis C virus, and other enveloped viruses. J Virol 2013; 87: 3640-3654
• 7 Herold BC, WuDunn D, Soltys N, Spear PG. Glycoprotein C of herpes simplex virus type 1 plays a principal role in the adsorption of virus to cells and in infectivity. J Virol 1991; 65: 1090-1098
• 8 Mårdberg K, Trybala E, Tufaro F, Bergström T. Herpes simplex virus type 1 glycoprotein C is necessary for efficient infection of chondroitin sulfate-expressing gro2C cells. J Gen Virol 2002; 83: 291-300
• 9 Herold BC, Visalli RJ, Susmarski N, Brandt CR, Spear PG. Glycoprotein C-independent binding of herpes simplex virus to cells requires cell surface heparan sulphate and glycoprotein B. J Gen Virol 1994; 75: 1211-1222
• 10 Peerboom N, Block S, Altgärde N, Wahlsten O, Möller S, Schnabelrauch M, Trybala E, Bergström T, Bally M. Binding kinetics and lateral mobility of HSV-1 on end-grafted sulfated glycosaminoglycans. Biophys J 2017; 113: 1223-1234
• 11 OʼDonnell CD, Tiwari V, Oh MJ, Shukla D. A role for heparan sulfate 3-O-sulfotransferase isoform 2 in herpes simplex virus type 1 entry and spread. Virology 2006; 346: 452-459
• 12 Warner MS, Geraghty RJ, Martinez WM, Montgomery RI, Whitbeck JC, Xu R, Eisenberg RJ, Cohen GH, Spear PG. A cell surface protein with herpesvirus entry activity (HveB) confers susceptibility to infection by mutants of herpes simplex virus type 1, herpes simplex virus type 2, and pseudorabies virus. Virology 1998; 246: 179-189
• 13 Spear PG. Herpes simplex virus: Receptors and ligands for cell entry. Cell Microbiol 2004; 6: 401-410
• 14 Pataki Z, Rebolledo Viveros A, Heldwein EE. Herpes simplex virus 1 entry glycoproteins form complexes before and during membrane fusion. mBio 2022; 13: e0203922
• 15 Weed DJ, Nicola AV. Herpes simplex virus membrane fusion. Adv Anat Embryol Cell Biol 2017; 223: 29-47
• 16 Leung DT, Sacks SL. Docosanol: A topical antiviral for herpes labialis. Expert Opin Pharmacother 2004; 5: 2567-2571
• 17 Pope LE, Marcelletti JF, Katz LR, Lin JY, Katz DH, Parish ML, Spear PG. The anti-herpes simplex virus activity of n-docosanol includes inhibition of the viral entry process. Antiviral Res 1998; 40: 85-94
• 18 Jaishankar D, Yakoub AM, Bogdanov A, Valyi-Nagy T, Shukla D. Characterization of a proteolytically stable D-peptide that suppresses herpes simplex virus 1 infection: Implications for the development of entry-based antiviral therapy. J Virol 2015; 89: 1932-1938
• 19 Dobson CB, Sales SD, Hoggard P, Wozniak MA, Crutcher KA. The receptor-binding region of human apolipoprotein E has direct anti-infective activity. J Infect Dis 2006; 193: 442-450
• 20 Berdugo M, Larsen IV, Abadie C, Deloche C, Kowalczuk L, Touchard E, Dubielzig R, Brandt CR, Behar-Cohen F, Combette JM. Ocular distribution, spectrum of activity, and in vivo viral neutralization of a fully humanized anti-herpes simplex virus IgG Fab fragment following topical application. Antimicrob Agents Chemother 2012; 56: 1390-1402
• 21 Clementi N, Criscuolo E, Cappelletti F, Quaranta P, Pistello M, Diotti RA, Sautto GA, Tarr AW, Mailland F, Concas D, Burioni R, Clementi M, Mancini N. Entry inhibition of HSV-1 and − 2 protects mice from viral lethal challenge. Antiviral Res 2017; 143: 48-61
• 22 Däumer MP, Schneider B, Giesen DM, Aziz S, Kaiser R, Kupfer B, Schneweis KE, Schneider-Mergener J, Reineke U, Matz B, Eis-Hübinger AM. Characterisation of the epitope for a herpes simplex virus glycoprotein B-specific monoclonal antibody with high protective capacity. Med Microbiol Immunol 2011; 200: 85-97
• 23 Gopinath SCB, Hayashi K, Kumar PKR. Aptamer that binds to the gD protein of herpes simplex virus 1 and efficiently inhibits viral entry. J Virol 2012; 86: 6732-6744
• 24 Antoine TE, Mishra YK, Trigilio J, Tiwari V, Adelung R, Shukla D. Prophylactic, therapeutic and neutralizing effects of zinc oxide tetrapod structures against herpes simplex virus type-2 infection. Antiviral Res 2012; 96: 363-375
• 25 Trigilio J, Antoine TE, Paulowicz I, Mishra YK, Adelung R, Shukla D. Tin oxide nanowires suppress herpes simplex virus-1 entry and cell-to-cell membrane fusion. PLoS One 2012; 7: e48147
• 26 Baram-Pinto D, Shukla S, Richman M, Gedanken A, Rahimipour S, Sarid R. Surface-modified protein nanospheres as potential antiviral agents. Chem Commun (Camb) 2012; 48: 8359-8361
• 27 Baram-Pinto D, Shukla S, Gedanken A, Sarid R. Inhibition of HSV-1 attachment, entry, and cell-to-cell spread by functionalized multivalent gold nanoparticles. Small 2010; 6: 1044-1050
• 28 Tiwari V, Darmani NA, Yue BYJT, Shukla D. In vitro antiviral activity of neem (Azardirachta indica L.) bark extract against herpes simplex virus type-1 infection. Phytother Res 2010; 24: 1132-1140
• 29 Bharitkar YP, Bathini S, Ojha D, Ghosh S, Mukherjee H, Kuotsu K, Chattopadhyay D, Mondal NB. Antibacterial and antiviral evaluation of sulfonoquinovosyldiacylglyceride: A glycolipid isolated from Azadirachta indica leaves. Lett Appl Microbiol 2014; 58: 184-189
• 30 Tiwari V, Shukla SY, Shukla D. A sugar binding protein cyanovirin-N blocks herpes simplex virus type-1 entry and cell fusion. Antiviral Res 2009; 84: 67-75
• 31 Katz DH, Marcelletti JF, Khalil MH, Pope LE, Katz LR. Antiviral activity of 1-docosanol, an inhibitor of lipid-enveloped viruses including herpes simplex. Proc Natl Acad Sci U S A 1991; 88: 10825-10829
• 32 Krawczyk A, Krauss J, Eis-Hübinger AM, Däumer MP, Schwarzenbacher R, Dittmer U, Schneweis KE, Jäger D, Roggendorf M, Arndt MAE. Impact of valency of a glycoprotein B-specific monoclonal antibody on neutralization of herpes simplex virus. J Virol 2010; 85: 1793-1803
• 33 Mosmann T. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J Immunol Methods 1983; 65: 55-63
• 34 Ha Y, Kim Y, Choi J, Hwang I, Ko JY, Jeon HK, Kim YJ. Evaluation of cytotoxicity, genotoxicity, and zebrafish embryo toxicity of mixtures containing Hyssopus officinalis, Morus alba, Engraulis japonicus, and 27 other extracts for cosmetic safety assessment. Mol Cell Toxicol 2021; 17: 221-232
• 35 Classen N, Ulrich D, Hofemeier A, Hennies MT, Hafezi W, Pettke A, Romberg ML, Lorentzen EU, Hensel A, Kühn JE. Broadly applicable, virus-free dual reporter assay to identify compounds interfering with membrane fusion: Performance for HSV-1 and SARS-CoV-2. Viruses 2022; 14: 1354
• 36 Classen N, Pitakbut T, Schöfbänker M, Kühn J, Hrincius ER, Ludwig S, Hensel A, Kayser O. Cannabigerol and cannabicyclol block SARS-CoV-2 cell fusion. Planta Med 2024; 90: 717-725
• 37 Loew D, Schrödtere A, Schwankle W, März RW. Measurement of the bioavailability of aescin-containing extracts. Methods Find Exp Clin Pharmacol 2000; 22: 537-542
• 38 Peñaranda Figueredo FA, Vicente J, Barquero AA, Bueno CA. Aesculus hippocastanum extract and the main bioactive constituent β-escin as antivirals agents against coronaviruses, including SARS-CoV-2. Sci Rep 2024; 14: 6418
• 39 Wu CY, Jan JT, Ma SH, Kuo CJ, Juan HF, Cheng YSE, Hsu HH, Huang HC, Wu D, Brik A, Liang FS, Liu RS, Fang JM, Chen ST, Liang PH, Wong CH. Small molecules targeting severe acute respiratory syndrome human coronavirus. Proc Natl Acad Sci U S A 2004; 101: 10012-10017
• 40 Michelini FM, Alché LE, Bueno CA. Virucidal, antiviral and immunomodulatory activities of β-escin and Aesculus hippocastanum extract. J Pharm Pharmacol 2018; 70: 1561-1571
• 41 Sirtori CR. Aescin: Pharmacology, pharmacokinetics and therapeutic profile. Pharmacol Res 2001; 44: 183-193
• 42 Lai ZZ, Shen HH, Lee YM. Inhibitory effect of β-escin on Zika virus infection through the interruption of viral binding, replication, and stability. Sci Rep 2023; 13: 10014
• 43 Salinas FM, Vázquez L, Gentilini MV, O’Donohoe A, Regueira E, Nabaes Jodar MS, Viegas M, Michelini FM, Hermida G, Alché LE, Bueno CA. Aesculus hippocastanum L. seed extract shows virucidal and antiviral activities against respiratory syncytial virus (RSV) and reduces lung inflammation in vivo. Antiviral Res 2019; 164: 1-11
• 44 Kim JW, Ha TKQ, Cho H, Kim E, Shim SH, Yang JL, Oh WK. Antiviral escin derivatives from the seeds of Aesculus turbinata Blume (Japanese horse chestnut). Bioorg Med Chem Lett 2017; 27: 3019-3025
• 45 Boukamp P, Petrussevska RT, Breitkreutz D, Hornung J, Markham A, Fusenig NE. Normal keratinization in a spontaneously immortalized aneuploid human keratinocyte cell line. J Cell Biol 1988; 106: 761-771
• 46 Pertel PE, Fridberg A, Parish ML, Spear PG. Cell fusion induced by herpes simplex virus glycoproteins gB, gD, and gH-gL requires a gD receptor but not necessarily heparan sulfate. Virology 2001; 279: 313-324
• 47 Babson AL, Phillips GE. A rapid colorimetric assay for serum lactic dehydrogenase. Clin Chim Acta 1965; 12: 210-215